Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

01/20/2017 | 04:53pm EDT
A trader passes by a screen displaying the tickers symbols for Bristol-Myers Squibb and Intelsat, Ltd. on the floor at the New York Stock Exchange

New YORK (Reuters) - Bristol-Myers Squibb Co (>> Bristol-Myers Squibb Co) shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's (>> Merck & Co., Inc.) leading position in the burgeoning immuno-oncolgy field.

New YORK (Reuters) - Bristol-Myers Squibb Co (>> Bristol-Myers Squibb Co) shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's (>> Merck & Co., Inc.) leading position in the burgeoning immuno-oncolgy field.

Lung cancer is by far the biggest oncology market and a handful of companies have been battling to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies.

Merck shares rose 3.6 percent to $62.53, while Bristol fell to $49.23.

Bristol-Myers earlier this month suggested it would seek a path to swift approval of an Opdivo/Yervoy combination in first-line non-small cell lung cancer (NSCLC) only to reverse course after reviewing available data. The company did not say whether the data was disappointing or merely insufficient to seek accelerated approval.

Cowen and Co analyst Steve Scala downgraded his rating on Bristol shares to "market perform" from "outperform" and lowered his price target on the stock to $65 from $85.

The quickly changing lung cancer market dynamics could hurt Bristol's earnings per share, Scala said.

The news followed Merck's surprise announcement last week that it had filed for a speedy U.S. approval of its Opdivo rival, Keytruda, in combination with chemotherapy in first-line lung cancer, and had received a May 10 regulatory decision date.

The Opdivo/Yervoy news "certainly kills any potential for commercial sales in front-line lung cancer for 2017" and could leave Bristol-Myers as the third or fourth entry instead of being first or a close second, Credit Suisse analyst Vamil Divan said. But it is by no means a death knell for Opdivo or the combination if the data is ultimately positive.

"This is lung cancer," Divan said. "If the combo ends up showing clearly superior efficacy in terms of overall survival, then doctors will switch to that."

Opdivo is approved for lung cancer in previously treated patients, as well as advanced melanoma, kidney and head and neck cancers and Hodgkin lymphoma.

Suntrust Robinson Humphrey analyst John Boris lowered his estimates for Opdivo sales in 2021 to $8.5 billion from $9.7 billion.

REVERSAL OF PECKING ORDER

Merck will not only likely be first with a first-line lung combination, but said it will be less expensive due to the lower cost of chemotherapy versus rivals' pairings of newer immuno-oncology drugs.

Bristol, which was first to market with potentially game-changing drugs that spur the immune system to fight cancer, was long perceived as the industry leader in immuno-oncology, with Merck hot on its heels and AstraZeneca Plc (>> AstraZeneca plc) and Roche Holding AG (>> Roche Holding Ltd.) playing catch-up.

That changed in August, when Bristol's Opdivo failed as a monotherapy against first-line lung cancer, where Merck's Keytruda succeeded, resetting the immuno-oncology pecking order.

Some analysts said the latest Opdivo setback was good news for AstraZeneca and Roche, allowing them to close the gap on Bristol-Myers.

However, Bernstein analyst Tim Anderson noted that Astra's combination includes a CTLA4 drug similar to Bristol's Yervoy.

"This could have negative implications for AstraZeneca, who similarly has CTLA4 combination at the heart of its IO platform," he wrote.

AstraZeneca shares fell 3.4 percent.

(Reporting by Bill Berkrot; Editing by Tom Brown and Lisa Shumaker)

By Bill Berkrot


ę Reuters 2017
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.12% 8307 Delayed Quote.15.78%
BRISTOL-MYERS SQUIBB COMPANY -0.34% 68.105 Delayed Quote.10.17%
DEERE & COMPANY -0.04% 354.56 Delayed Quote.31.83%
MERCK & CO., INC. -0.30% 77.2996 Delayed Quote.-5.21%
NEXT PLC -0.12% 8076 Delayed Quote.14.20%
SEEK LIMITED 0.72% 30.6 End-of-day quote.7.26%
SWITCH, INC. 0.36% 20.82 Delayed Quote.26.82%
THE LEAD CO., INC. -0.15% 662 End-of-day quote.-21.19%
All news about BRISTOL-MYERS SQUIBB COMPANY
07/23BRISTOL MYERS SQUIBB : Statement on Opdivo« (nivolumab) Monotherapy Post-Sorafen..
PU
07/19PORTAGE BIOTECH CEO INTERVIEW EXPLAI : Prtg)
AQ
07/19COMPUGEN : Doses First Patient in Expansion Arm of Study Evaluating Triple Combi..
MT
07/19BRISTOL MYERS SQUIBB : MPN Hub continues to enhance global knowledge of myelopro..
AQ
07/19AML Hub continues to enhance global knowledge of acute myeloid leukemia throu..
AQ
07/16BRISTOL MYERS SQUIBB : Says Study of Opdivo Plus Yervoy Against Carcinoma Did No..
MT
07/16Bristol Myers Squibb Cancer Drug Study Falls Short of Endpoints
DJ
07/16BRISTOL MYERS SQUIBB : Provides Update on CheckMate -651 Trial Evaluating Opdivo..
BU
07/16Bristol-Myers Squibb Company Provides Update on Checkmate -651 Trial Evaluati..
CI
07/14Ribon Therapeutics, Inc. announced that it has received $65 million in fundin..
CI
More news
Financials (USD)
Sales 2021 46 031 M - -
Net income 2021 7 797 M - -
Net Debt 2021 28 265 M - -
P/E ratio 2021 20,1x
Yield 2021 2,84%
Capitalization 153 B 153 B -
EV / Sales 2021 3,93x
EV / Sales 2022 3,50x
Nbr of Employees 30 250
Free-Float 76,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 68,34 $
Average target price 75,18 $
Spread / Average Target 10,0%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY10.17%149 020
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246